Table 5

Multivariate analysis
PSA Progression-Free Survival
Model 1 Model 2 Model 3
HR (95%CI) p= HR (95%CI) p= HR (95%CI) p=
PSA,ng/ml
≤10ng/ml 1.0 1.0 1.0
>10ng/ml 1.39 (0.66-2.96) 0.4 1.25 (0.58-2.68) 0.6 1.29 (0.60-2.78) 0.5
Extra-prostatic extension
Yes 1.0 1.0 1.0
No 3.30 (1.29-8.47) 0.01 3.21 (1.27-8.07) 0.01 3.20 (1.27-8.09) 0.01
Pelvic nodes involved
N0 1.0 1.0 1.0
N+ 1.55 (0.68-3.55) 0.3 1.37 (0.60-3.14) 0.4 1.39 (0.61-3.18) 0.4
Surgical margins involved
No 1.0 1.0 1.0
Yes 0.75 (0.31-1.81) 0.5 0.72 (0.31-1.67) 0.4 0.68 (0.29-1.62) 0.4
Seminal vesicles involved
No 1.0 1.0 1.0
Yes 0.77 (0.35-1.70) 0.5 0.64 (0.28-1.44) 0.3 0.64 (0.28-1.43) 0.3
Gleason score
<7 1.0
≥7 2.02 (0.90-4.54) 0.09
Gleason score
≤7 1.0
>7 3.29 (1.62-6.65) 0.001
Gleason score
<7 1.0 0.03
=7 1.32 (0.54-3.26) 0.5
>7 3.89 (1.58-9.54) 0.003
Stromal -Epithelial IRS Score
=12/≤2 1.0 0.08 1.0 0.2 1.0 0.2
<12/≤2 0.47 (0.19-1.17) 0.1 0.52 (0.20-1.33) 0.2 0.53 (0.21-1.37) 0.2
=12/>2 0.14 (0.01-1.33) 0.09 0.19 (0.02-1.89) 0.2 0.19 (0.02-1.89) 0.2
<12/>2 0.09 (0.01-0.77) 0.03 0.11 (0.01-1.10) 0.06 0.12 (0.01-1.11) 0.06

Abbreviations:HR,Hazard Ratio;CI ,Confidence Interval; PSA,Prostate-specific antigen;IRS, Immuno-reactive score.

Nuzzo et al.

Nuzzo et al. BMC Cancer 2012 12:625   doi:10.1186/1471-2407-12-625

Open Data